Drug Profile
Research programme: antibacterial wound infection therapies - Atterx Biotherapeutics
Alternative Names: Acinetobacter baumannii combat infections therapy - Atterx Biotherapeutics; Atterx Biotherapeutics 2041; Atterx Biotherapeutics 2043; Atterx Biotherapeutics B-040405; Atterx Biotherapeutics B-070604; Atterx Biotherapeutics B-120900; B-4474; Conjucin Agents; Conjucins; Wound infections therapies - Atterx BiotherapeuticsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ConjuGon
- Developer Atterx Biotherapeutics
- Class
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Wound infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Wound-infections in USA
- 17 Aug 2005 Preclinical trials in Urinary tract infections in USA (unspecified route)
- 17 Aug 2005 Preclinical trials in Wound infections in USA (unspecified route)